

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Mandatory vaccination prior to or at initiation of therapy with eculizumab (ECZ)¹

Meningococcal vaccine					
Age	Brand (Expert group)	Doses	Frequency	Booster	Comments
2-9 months	Menveo (CDC)	2-4	2 or 3 doses are given ≥ 8 wk apart, such that at least one dose is given at ≥ 7 months; another dose is given (≥ 12 -wk later) at ≥ 1 -yr-old	If ECZ continued: Age <7-yr: At 3-yr after primary vaccination; then q 5 yr	Conjugate vaccines (Menveo [®] or Menactra [®]), are preferred to polysaccharide vaccines; in children ≥ 2 yr, the 2-dose schedule (CDC) is off-label; Menactra should not be given along with PCV (ensure gap of ≥ 4 -wk between doses)
9-23 months	Menveo (CDC)	2	≥ 12 wk apart (second dose at ≥ 1 -yr-old)	Age ≥ 7 -yr: At 5-yr after primary vaccination; then q 5-yr	
	Menactra (CDC, IAP)				
≥ 2 years	Menveo (CDC, IAP)	1-2	1 dose (IAP); 1-2 doses ≥ 8 wk apart (CDC)		
	Menactra (CDC)		1-2 doses ≥ 8 wk apart (CDC)		
Pneumococcal vaccine					
Age	Primary immunization status	Doses	Schedule	Booster	Comments
<6 months	Not received or incompletely immunized	3	PCV: 6, 10 and 14 wk or 3 doses ≥ 4 wk apart (IAP) PCV: 2, 4 and 6 months or 3 doses ≥ 8 wk apart (CDC)	PCV: At 12-15 months PPSV23: At ≥ 2 yr, ≥ 8 weeks after PCV dose	13-valent vaccine (Prevenar13 [®]) is preferred to 10-valent vaccines (Prevenar10 [®] or Pneumosil [®]) across ages; all 3 vaccines suitable for primary immunization in infancy; Pneumosil [®] not used >2-yr-old; Prevenar13 [®] preferred to Prevenar10 [®] in children 2-5 yr-old; only Prevenar13 [®] allowed >5-yr; 21-, 20- or 15-valent vaccines will be preferred to 13-valent when
7-11 months	If not received or incompletely immunized	2	PCV: ≥ 4 wk apart (CDC, IAP)		
12-23 months	Received primary immunization in first year	1	PCV: 1 dose (CDC, IAP)	PPSV23: ≥ 8 weeks after PCV dose	
	If not received or incompletely immunized	2	PCV: ≥ 8 wk apart (CDC, IAP)		
24-72 months	Received primary immunization in first year +/- booster in second year	1	PCV: 1 dose (CDC, IAP)	PPSV23: 1 dose ≥ 8 weeks after PCV dose	
	If not received or incompletely immunized in first year	2	PCV: 2 doses ≥ 8 weeks apart		
≥ 6 years	Received primary immunization in first year +/- booster in second year	0	None	PPSV23: 1 dose	

	If not received or incompletely immunized in first year	1	PCV13: 1 dose	PPSV23: 1 dose \geq 8 weeks after PCV dose; another booster after 5 yr if ECZ continued	available (not yet licensed in India)
<i>Hemophilus influenza B (HiB) vaccine</i>					
<6 months	Not applicable	3	6, 10 and 14 wk or 3 doses \geq 4 wk apart (IAP) 2, 4 and 6 months or 3 doses \geq 8 wk apart (CDC)	HiB: 12-15 months (CDC) or 16-18 months (IAP)	In infancy, HiB vaccine is administered as part of pentavalent vaccine in the National Immunization Schedule
7-11 months	If not received or incompletely immunized	2	\geq 4 wk apart (CDC, IAP)		
12-59 months	Received \geq 2 doses of primary immunization in first year and booster at \geq 1-yr	0	None	None	
	Received \geq 2 doses of primary immunization in first year and no booster	1	One dose \geq 8 weeks after the last dose	None	
	If not received primary immunization in first year or received one dose in first year	2	\geq 8 weeks apart		
\geq 5 years	If received \geq 2 doses of primary immunization in first year and booster	0	None		
	If not received primary immunization in first year or missed booster	1	One dose		
Influenza	<8-yr-old: Two doses \geq 4 weeks apart; then one dose annually >8-yr-old: One dose annually				
Hepatitis B	If anti-HBs titre <10 mIU/ml, give at 0,1 and 6 months; prefer double dose (1 mL); ensure adequate anti-HBs antibody titer subsequently				
Other vaccines	All indicated vaccines should be given, including live vaccines (benefits outweigh risk) Prefer administering meningococcal vaccine before and with DPT vaccine				

¹Ideally performed >2 weeks before the first dose of eculizumab; should administer on or before the first dose of therapy; initiate antibiotic prophylaxis simultaneously (**Table 2**)
CDC Center for Disease Control; DPT diphtheria pertussis tetanus; IAP Indian Academy of Pediatrics; PCV pneumococcal conjugate vaccine; PPSV23 pneumococcal polysaccharide vaccine